Kevin Ho, MD
Dr. Ho is combining multi-dimensional electronic health record-based algorithms to identify and subtype chronic kidney diseases together with MyCode genetic data to better understand the associated underlying molecular pathways through genome-wide association analysis. Geisinger’s MyCode Community Health Initiative (MyCode) has enrolled over 150,000 individuals for whole exome sequencing and whole genome array genotyping. Genetic data are linked to electronic health records (EHR) of over 3 million individuals since 1996 organized in a clinical data warehouse. His current interests have been in synthesizing phenotyping and genetic data with a focus on Type 2 diabetic kidney disease, Fabry-associated kidney disease, and chronic kidney disease. He is a member of the international CKDGen Consortium with its mission to identify novel genetic loci associated with kidney function and kidney disease through GWAS meta-analyses and the Chronic Kidney Disease Prognosis Consortium (CKD-PC), a participant in the eMERGE Network, and PI for the Fabry Registry at Geisinger. On the clinical side, he and his collaborators are recipients of a major grant from the Geisinger Health Plan to develop and study the effectiveness of integrated EHR-based bioinformatics including advanced predictive analytics, an interactive registry, and a clinical intervention pathway targeting patients developing acute kidney injury and its clinical sequelae at Geisinger to improve patient care and clinical outcomes.
Electronic health record phenotyping, phenomics, and genetics of kidney disease, diabetic kidney disease, acute kidney Injury, Fabry Disease
EHR Phenotyping of Kidney Disease, Genetic Kidney Disorders, Chronic Kidney Disease, Renal Electrolyte Disorders, Quality Improvement Initiatives in Kidney Disease
Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, [...] Ho K, Morris AP, Devuyst O, Akilesh S, Pendergrass SA, Sim X, Böger CA, Okada Y, Edwards TL, Snieder H, Stefansson K, Hung AM, Heid IM, Scholz M, Teumer A, Köttgen A, Pattaro C. A catalogue of molecular targets for kidney function from genetic analyses of a million individuals. Nature Genetics 2019; (Accepted for publication)
Morgan E Grams, Yingying Sang, Shoshana H Ballew, Juan Jesus Carrero, Ognjenka Djurdjev, Hiddo JL Heerspink, Kevin Ho, Sadayoshi Ito, Angharad Marks, David Naimark, Danielle M Nash, Sankar D Navaneethan, Mark Sarnak, Benedicte Stengel, Frank LJ Visseren, Angela Yee Moon Wang, Anna Köttgen, Andrew S Levey, Mark Woodward, Kai-Uwe Eckardt, Brenda Hemmelgarn, Josef Coresh. Predicting timing of adverse events in CKD with severely decreased GFR. Kidney International. 2018; (accepted)
Jason C George, Prince Mohan, Kevin Ho. Antineutrophil cytoplasmic antibody and multiple sclerosis. Kidney International Reports. 2018; (accepted)
Soman S, Yee J, Ho K. Quality improvement initiatives in kidney disease. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL, eds. Brenner and Rector's The Kidney. 10th ed. Philadelphia, PA: Elsevier; October 2015.
EducationAB, Harvard College, 1978-1982
MD, Columbia School of Medicine, 1983-1987
Internal Medicine Residency, New York Presbyterian Hospital, 1987-1990
Nephrology Research Fellowship, Harvard Medical School, 1990-1993
Nephrology Clinical Fellowship, Harvard Medical School, 1993-1994